welcome to the whwhole story. i m anderson cooper. you ve probably heard of magic mushrooms, mushrooms which contain psilocybin, a natural substance. they became popular in the united states in the 1960s, but in the last decade, there s been an increasing amount of research into psilocybin to see if it can help treat depression, anxiety, and substance abuse. magic mushrooms are still illegal on the federal level but a few states have decriminalized them. oregon became the first state to use them in licensed therapy centers. there s still a lot we don t know about psilocybin s effect on the brain long-term. many are asking if it s too soon to offer these treatments. over the next hour, cnn s david culver takes us into this fascinating new world and takes us on a mind-altering journey of his own. embarking on a psychedelic trip thank you. requires a willingness to be vulnerable, to hold nothing back. this wasn t easy, i imagine, for any of you to say, let me jump
story. i m anderson cooper. you ve probably heard of magic mushrooms. mushrooms which contain psilocybin, a natural substance that can cause hallucinations when ingested. magic mushrooms became popular in the united states in the 1960s. but in the last decade there s been an increasing amount of research into psilocybin to see if it could help treat depression, anxiety and substance abuse. magic mushrooms are still illegal on the federal level but a few states have decriminalized them and this year oregon became the first state to legalize the use of psilocybin in licensed therapy centers. there s still a lot we don t know about psilocybin s effect on the brain long term. and many are asking if it s too soon to offer these treatments. over the next hour cnn s david culver takes us into this fascinating new world and takes us on a mind-altering journey of his own. embarking on a psychedelic trip thank you. requires a willingness to be vulnerable, to hold nothing b
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 .